Search

Displaying results 4411 - 4420 of 10000 in total
  1. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  2. Drug

    AC-100

    go.drugbank.com/drugs/DB05671
    Investigational

    AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein).

  3. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. … The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.

  4. Drug

    TC-5231

    go.drugbank.com/drugs/DB05333
    Experimental

    TC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine. … TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder).

  5. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.

  6. Drug

    EHC18

    go.drugbank.com/drugs/DB05114
    Experimental

    EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.

  7. Drug

    ACE393

    go.drugbank.com/drugs/DB05071
    Investigational

    ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world.

  8. Drug

    SSR-126517E

    go.drugbank.com/drugs/DB05362
    Experimental

    SSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.

  9. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.

  10. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation